Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

81. Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone

Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone European Medicines Agency - News and Events - Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone Search for medicines Main navigation News and press releases Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone Press release 09/03/2018 Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone Ongoing (...) clinical study shows an increased risk of death and fractures with the combination The European Medicines Agency (EMA) has recommended contraindicating the use of the prostate cancer medicine Xofigo (radium-223 dichloride) with Zytiga (abiraterone acetate) and prednisone/prednisolone, due to an increased risk of death and fractures with this combination. EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has reviewed the preliminary data from an ongoing clinical study in metastatic prostate

European Medicines Agency - EPARs2018

82. Initial toxicity, quality-of-life outcomes, and dosimetric impact in a randomized phase 3 trial of hypofractionated versus standard fractionated proton therapy for low-risk prostate cancer

Initial toxicity, quality-of-life outcomes, and dosimetric impact in a randomized phase 3 trial of hypofractionated versus standard fractionated proton therapy for low-risk prostate cancer Redirecting

Advances in radiation oncology2018 Full Text: Link to full Text with Trip Pro

83. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. Background Apalutamide, a competitive inhibitor of the androgen receptor, is under development for the treatment of prostate cancer. We evaluated the efficacy of apalutamide in men with nonmetastatic castration-resistant prostate cancer who were at high risk for the development of metastasis. Methods We conducted a double-blind, placebo-controlled, phase 3 trial involving men with nonmetastatic castration-resistant prostate (...) cancer and a prostate-specific antigen doubling time of 10 months or less. Patients were randomly assigned, in a 2:1 ratio, to receive apalutamide (240 mg per day) or placebo. All the patients continued to receive androgen-deprivation therapy. The primary end point was metastasis-free survival, which was defined as the time from randomization to the first detection of distant metastasis on imaging or death. Results A total of 1207 men underwent randomization (806 to the apalutamide group and 401

NEJM2018

85. Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer

Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer 29185869 2018 02 14 1527-7755 36 6 2018 Feb 20 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. 581-590 10.1200/JCO.2017.74.2940 Purpose It is clinically challenging to integrate genomic (...) -classifier results that report a numeric risk of recurrence into treatment recommendations for localized prostate cancer, which are founded in the framework of risk groups. We aimed to develop a novel clinical-genomic risk grouping system that can readily be incorporated into treatment guidelines for localized prostate cancer. Materials and Methods Two multicenter cohorts (n = 991) were used for training and validation of the clinical-genomic risk groups, and two additional cohorts (n = 5,937) were used

EvidenceUpdates2018

86. Comparative effectiveness review of cryoablation for salvage treatment of recurrent prostate cancer following radiotherapy

Comparative effectiveness review of cryoablation for salvage treatment of recurrent prostate cancer following radiotherapy Comparative effectiveness review of cryoablation for salvage treatment of recurrent prostate cancer following radiotherapy Comparative effectiveness review of cryoablation for salvage treatment of recurrent prostate cancer following radiotherapy HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Comparative effectiveness review of cryoablation for salvage treatment of recurrent prostate cancer following radiotherapy. Lansdale: HAYES, Inc. Directory Publication. 2017 Authors' conclusions Cryoablation of the prostate gland provides a minimally invasive treatment option for the management of localized prostate cancer. The technique uses percutaneously inserted cryoprobes to freeze and thereby

Health Technology Assessment (HTA) Database.2018

87. Comparative effectiveness review of cryoablation for primary treatment of localized prostate cancer

Comparative effectiveness review of cryoablation for primary treatment of localized prostate cancer Comparative effectiveness review of cryoablation for primary treatment of localized prostate cancer Comparative effectiveness review of cryoablation for primary treatment of localized prostate cancer HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation HAYES, Inc. Comparative effectiveness review of cryoablation for primary treatment of localized prostate cancer. Lansdale: HAYES, Inc. Directory Publication. 2017 Authors' conclusions The publication date for this report is June 8, 2017, with a corrigendum issued on July 27, 2017. See Publication History for details. Cryoablation of the prostate gland provides a minimally invasive treatment option for the management of localized prostate cancer. The technique uses percutaneously

Health Technology Assessment (HTA) Database.2018

88. Ablative techniques for the treatment of localised prostate cancer

Ablative techniques for the treatment of localised prostate cancer Health Policy Advisory Committee on Technology Technology Brief Update Ablative techniques for the treatment of localised prostate cancer December 2016 © State of Queensland (Queensland Department of Health) 2016 This work is licensed under a Creative Commons Attribution Non-Commercial No Derivatives 3.0 Australia licence. In essence, you are free to copy and communicate the work in its current form for non-commercial purposes (...) from the Australian Safety and Efficacy Register of New Interventional Procedures – Surgical (ASERNIP-S). Ablative techniques for localised prostate cancer: December 2016 i 2016 Summary of findings Currently, the most common treatments for localised Prostate cancer (PCa) are radical prostatectomy, active surveillance, external beam radiation therapy and brachytherapy. Focal therapy could potentially prevent complications associated with whole-gland therapy (urinary incontinence/retention

COAG Health Council - Horizon Scanning Technology Briefs2018

89. Risk of prostate cancer across different racial/ethnic groups in men with diabetes: a retrospective cohort study

Risk of prostate cancer across different racial/ethnic groups in men with diabetes: a retrospective cohort study 29078006 2017 12 11 1464-5491 35 1 2018 Jan Diabetic medicine : a journal of the British Diabetic Association Diabet. Med. Risk of prostate cancer across different racial/ethnic groups in men with diabetes: a retrospective cohort study. 107-111 10.1111/dme.13536 To examine the associations between prostate cancer, diabetes and race/ethnicity. Using administrative data from British (...) Columbia, Canada for the period 1994 to 2012, we identified men aged ≥50 years with and without diabetes. Validated surname algorithms identified men as Chinese, Indian or of other race/ethnicity. Multivariable Cox regression was used to estimate adjusted risks of prostate cancer according to diabetes status and race/ethnicity. Our cohort of 160 566 men had a mean (sd) age of 64.7 (9.4) years and a median of 9 years' follow-up. The incidence rates of prostate cancer among those with and without

EvidenceUpdates2018 Full Text: Link to full Text with Trip Pro

90. Localised prostate cancer - immediate treatment, or not?

Localised prostate cancer - immediate treatment, or not? Prescrire IN ENGLISH - Spotlight ''In the February issue of Prescrire International: Localised prostate cancer - immediate treatment, or not?'', 1 February 2018 {1} {1} {1} | | > > > In the February issue of Prescrire International: Localised prostate cancer - immediate treatment, or not? Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |  (...)  |   |   |  Spotlight In the February issue of Prescrire International: Localised prostate cancer - immediate treatment, or not? FREE DOWNLOAD In patients with localised prostate cancer, the principal therapeutic options are: monitoring without initial treatment, prostatectomy and radiotherapy. Results of a comparative randomised trial have provided some useful data for providing information to patients. Full text available for free download. Summary In a randomised trial

Prescrire2018

91. Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database

Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database Redirecting

Advances in radiation oncology2018 Full Text: Link to full Text with Trip Pro

92. Current and Future Burden of Prostate Cancer in Songkhla, Thailand: Analysis of Incidence and Mortality Trends From 1990 to 2030

Current and Future Burden of Prostate Cancer in Songkhla, Thailand: Analysis of Incidence and Mortality Trends From 1990 to 2030 ');//--> ');//--> Search in: Menu Captcha ASCO Family of Sites Journals Publications Education Other Sites 2318 Mill Road, Suite 800, Alexandria, VA 22314 © 2018 American Society of Clinical Oncology |

Journal of global oncology2018 Full Text: Link to full Text with Trip Pro

93. Targeting protein myristoylation for the treatment of prostate cancer

Targeting protein myristoylation for the treatment of prostate cancer 3 www.impactjournals.com/oncoscience Oncoscience www.impactjournals.com/oncoscience/ Oncoscience, Vol. 5(1-2), January 2018 Targeting protein myristoylation for the treatment of prostate cancer Essilvo Sulejmani and Houjian Cai Chemotherapeutic agents for the treatment of various stages of prostate cancer have shown promising effects on overall survival of the patient. Emerging in 2004, the taxanes docetaxel and cabazitaxel (...) have become the standard chemotherapeutic approaches. These agents have been explored for treatment of metastatic castration-sensitive or resistant prostate cancer. Docetaxel in combination with androgen deprivation therapy has consistently shown improvement in the overall survival for eligible patients with high-volume or earlier stages of metastatic castration-sensitive prostate cancer. Cabazitaxel has been used mainly for post-docetaxel treatment or following resistance to docetaxel [1]. While

Oncoscience2018 Full Text: Link to full Text with Trip Pro

94. Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts.

Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. OBJECTIVES: To develop and validate a genetic tool to predict age of onset of aggressive prostate cancer (PCa) and to guide decisions of who to screen and at what age. DESIGN: Analysis of genotype, PCa status, and age to select single nucleotide polymorphisms (SNPs) associated with diagnosis. These polymorphisms were incorporated into a survival analysis to estimate (...) their effects on age at diagnosis of aggressive PCa (that is, not eligible for surveillance according to National Comprehensive Cancer Network guidelines; any of Gleason score ≥7, stage T3-T4, PSA (prostate specific antigen) concentration ≥10 ng/L, nodal metastasis, distant metastasis). The resulting polygenic hazard score is an assessment of individual genetic risk. The final model was applied to an independent dataset containing genotype and PSA screening data. The hazard score was calculated

BMJ2018 Full Text: Link to full Text with Trip Pro

95. Screening for Prostate Cancer*

Screening for Prostate Cancer* Screening for Prostate Cancer | National Guideline Clearinghouse success fail JUL Aug 12 2018 2019 30 Sep 2016 - 13 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites for the sake of history and digital heritage. The group is 100% composed of volunteers and interested parties, and has expanded (...) ? The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018 because federal funding through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our . Guideline Synthesis Screening for Prostate Cancer Guidelines Being Compared: American College of Physicians (ACP) Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. 2013 Apr

National Guideline Clearinghouse (partial archive)2018

96. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, ph

Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, ph 29033099 2017 12 15 2017 12 15 1474-5488 18 11 2017 Nov The Lancet. Oncology Lancet Oncol. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant (...) prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial. 1532-1542 S1470-2045(17)30605-8 10.1016/S1470-2045(17)30605-8 Docetaxel and cabazitaxel improve overall survival compared with mitoxantrone in patients with metastatic castration-resistant prostate cancer. Custirsen (OGX011) is a second generation highly specific antisense oligonucleotide that inhibits the production of clusterin, an antiapoptotic protein that is upregulated in response

EvidenceUpdates2018

97. Prostate cancer

Prostate cancer Prostate cancer - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Prostate cancer Last reviewed: August 2018 Last updated: July 2018 Summary Second leading cause of cancer mortality in men in the US. Uncommon in men aged under 50 years. Prostate-specific antigen and digital rectal examination are key diagnostic tools used in screening. Management may be expectant or definitive. In the US, overall 5-year (...) survival rate is around 100% for local- and regional-stage prostate cancer, and around 30% for distant-stage prostate cancer (based on data from 2007 to 2013). Definition A malignant tumour of glandular origin, situated in the prostate. It is most commonly seen in older men; between 2011 and 2015 the median age at diagnosis in the US was 66 years. National Cancer Institute; Surveillance, Epidemiology, and End Results program (SEER). SEER stat fact sheets: prostate cancer. 2018 [internet publication

BMJ Best Practice2018

98. Post-treatment impact and needs of prostate cancer survivors in Malaysia; a qualitative study

Post-treatment impact and needs of prostate cancer survivors in Malaysia; a qualitative study 29527275 2018 11 14 1985-207X 12 3 2017 Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia Malays Fam Physician Post-treatment impact and needs of prostate cancer survivors in Malaysia; a qualitative study. 18-24 There are limited studies conducted on the needs of cancer survivors in developing countries like Malaysia. This qualitative study aimed (...) at exploring the post-treatment impact and needs of prostate cancer survivors. A qualitative study design was used. One in-depth interview and four focus group discussions were conducted with 24 prostate cancer survivors (age range: 58-79 years) from government and private hospitals in Malaysia in 2013. Trained researchers used a topic guide to guide the interviews, which were audio-recorded, transcribed verbatim, checked and managed with Nvivo 10 software. A thematic approach was used to analyse the data

Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia2017 Full Text: Link to full Text with Trip Pro

99. Outcomes and toxicity from a prospective study of moderately hypofractionated radiation therapy for prostate cancer

Outcomes and toxicity from a prospective study of moderately hypofractionated radiation therapy for prostate cancer Redirecting

Advances in radiation oncology2017 Full Text: Link to full Text with Trip Pro

100. Destroying the androgen receptor (AR)-potential strategy to treat advanced prostate cancer

Destroying the androgen receptor (AR)-potential strategy to treat advanced prostate cancer 175 www.impactjournals.com/oncoscience Oncoscience www.impactjournals.com/oncoscience/ Oncoscience, Vol. 4(11-12), November 2017 Destroying the androgen receptor (AR)-potential strategy to treat advanced prostate cancer Ramesh Narayanan, Suriyan Ponnusamy, Duane D. Miller Recently, a library of selective androgen receptor degraders (SARDs) that degrade the full length and splice variant ARs (AR-SVs (...) -resistant prostate cancer (CRPC) led to development of the next- generation AR competitive antagonist enzalutamide and the CYP17A1 inhibitor abiraterone [2]. This renewed interest in targeting the AR axis has significantly increased the efforts to discover AR antagonists. Men treated with enzalutamide and abiraterone yet are either non-responsive or develop resistance are heterogeneous in nature. Some of the observed phenotypes include a neuroendocrine type in which AR is not thought to be a driver, AR

Oncoscience2017 Full Text: Link to full Text with Trip Pro